[HTML][HTML] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser, SN Freiberger…�- Nature�…, 2023 - nature.com
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
[HTML][HTML] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with�…
[HTML][HTML] Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
K Zhou, S Li, Y Zhao, K Cheng�- Frontiers in Immunology, 2023 - frontiersin.org
Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have
become the frontier of cancer treatment and successfully prolonged the survival of patients�…
become the frontier of cancer treatment and successfully prolonged the survival of patients�…
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
RJ Walsh, RA Soo�- Therapeutic advances in medical�…, 2020 - journals.sagepub.com
The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not�…
greatly with the advent of immune checkpoint inhibitors. However, many patients do not�…
Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
J Frigola, A Navarro, C Carbonell, A Callejo…�- Molecular�…, 2021 - Wiley Online Library
Immunotherapy has transformed advanced non‐small cell lung cancer (NSCLC) treatment
strategies and has led to unprecedented long‐lasting responses in some patients. However�…
strategies and has led to unprecedented long‐lasting responses in some patients. However�…
[HTML][HTML] Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non�…
K Hosoya, D Fujimoto, T Morimoto, T Kumagai…�- BMC cancer, 2021 - Springer
Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer
chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are�…
chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are�…
[HTML][HTML] Low infiltration of CD8+ PD-L1+ T cells and M2 macrophages predicts improved clinical outcomes after immune checkpoint inhibitor therapy in non-small cell�…
L Li, G Lu, Y Liu, L Gong, X Zheng, H Zheng…�- Frontiers in�…, 2021 - frontiersin.org
Background Many clinical studies have shown that patients with non-small cell lung
carcinoma (NSCLC) can benefit from immune checkpoint inhibitor (ICI) therapy; however�…
carcinoma (NSCLC) can benefit from immune checkpoint inhibitor (ICI) therapy; however�…
Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood�…
However, molecular determinants of response to ICIs remain incompletely understood�…
[HTML][HTML] Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Purpose: We sought to identify features of patients with advanced non–small cell lung
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors�…
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors�…
[HTML][HTML] Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
X Pu, L Wu, D Su, W Mao, B Fang�- BMC cancer, 2018 - Springer
Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the
treatment of lung cancer, the leading cause of cancer-related deaths in the United States�…
treatment of lung cancer, the leading cause of cancer-related deaths in the United States�…